Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
about
Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000Adenosine receptors as therapeutic targetsAdenosine kinase: exploitation for therapeutic gain.Recent developments in adenosine receptor ligands and their potential as novel drugsEmerging adenosine receptor agonistsAnticonvulsant activity of B2, an adenosine analog, on chemical convulsant-induced seizuresStructure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsEnduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain.Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactionsStructure based prediction of subtype-selectivity for adenosine receptor antagonistsDifferential effects of adenosine A2a and A2b receptors on cardiac contractilityInternational Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an updateSynthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition processFunctionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancersMolecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor.Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists.Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.Introduction to adenosine receptors as therapeutic targets.Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonistsOptimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.Application of the functionalized congener approach to dendrimer-based signaling agents acting through A(2A) adenosine receptors.Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.Targeting adenosine receptors in the development of cardiovascular therapeutics.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.Characterization of the Drosophila adenosine receptor: the effect of adenosine analogs on cAMP signaling in Drosophila cells and their utility for in vivo experiments.Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine.The Effects of the Adenosine Receptor Antagonists on the Reverse of Cardiovascular Toxic Effects Induced by Citalopram In-Vivo Rat Model of PoisoningThe role of adenosine receptors and endogenous adenosine in citalopram-induced cardiovascular toxicity.Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigsAdenosine: Direct and Indirect Actions on Gastric Acid Secretion.An allosteric modulator of the adenosine A1 receptor improves cardiac function following ischaemia in murine isolated hearts.
P2860
Q21262008-E96E829E-388F-432B-B557-068783ACDE91Q24632095-F089197A-AEE4-456D-A1C0-457674F87D1CQ26852056-A5A51368-357D-4FE7-BE67-7254E26D37EAQ27687253-43F106C5-E53B-44D7-9CA2-A1A79D5E1502Q28249111-CDE4D724-4E23-445B-ADFA-90D6B8B49E25Q28534300-7D1F0CE3-A259-451C-AF4C-1D9B674ABF02Q30435017-5B4F362B-49E5-4080-9E04-5ACA12FE855DQ30486707-CE23BAB1-A042-43CA-9AF1-1E593814140BQ33562058-8747C7B1-50CC-4C10-A722-D4AC2B228299Q33754822-1E852F39-2BCF-4B93-AECB-64EDA054E564Q34306247-ED3A8A38-3BCE-4F1F-B361-7E5CF700B83FQ34426244-EC3670A6-54CC-4130-9292-60194645B645Q34701303-1B634B14-DC89-4624-9977-DEB1FA36FC14Q35020369-88CA510D-E39C-4808-922B-E168DE2BCEDDQ35154034-C7A6F88F-F07F-401A-9854-A267E3887EA1Q35549895-89AB900A-5825-420F-BFF0-22B1FC13309FQ36083075-B4E7BBCF-18EB-406B-A233-49F172B4C3C2Q36116925-7CB4114A-681A-4B9F-9C5B-C6070A4A77BEQ36153376-AC46DDAA-1530-4473-86CA-1356DEDBA64FQ36281650-847EB03B-4E55-4DF4-A44A-22A5CB08D3BDQ36294009-998B92C4-D432-43A1-ABB8-F725DA6553A5Q36294092-4A87A9D4-E346-41CD-871A-4EB07841131CQ36327179-76036693-BB29-4136-9776-D2D4CCFC77FDQ36343219-DBCDAC42-23CF-469C-913D-E5C2C1583F56Q36626953-CF3CDBD5-83ED-43AD-8A98-CE4C26F3D7BCQ36899701-AB064801-B46A-4122-AF63-E92C564E93A2Q37003068-C364CDDA-7ABE-4D12-AEDD-9CD2F14C6ABEQ37268033-28A862CC-5D0D-42DC-8480-178FB4A24C13Q37291594-7B79B21B-C12F-46D2-977B-7FAC8FF6E7CEQ37381136-B7BE0B02-211A-4E26-8A9F-831920C837FFQ37990558-308D54B5-278A-4B77-ABFF-6526B7A10B35Q38584194-B7F898E3-6A8B-4ABE-B680-3DBF5E90D761Q39148961-05B987B8-4127-43AE-986A-B989A7EB4EF7Q39392857-88548582-436F-4C8D-BA00-BFAABBCE9133Q39393394-6E11FBAF-C2B4-4EDF-8634-7BAFAAFE3C48Q41167029-F3230DD2-C3B7-4E59-A30B-36E7B6A1632AQ41873724-44EB94FF-2169-4F7D-8D08-6DD97F1E8CBDQ41985575-98F41933-6A03-489C-A4BA-7C09C6CF2B31Q42364567-AA4EB168-9813-45A3-83B5-D3F422526694Q42922738-787504CC-1212-4DC1-A76C-7CF3FC6E1020
P2860
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
@ast
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
@en
type
label
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
@ast
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
@en
prefLabel
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
@ast
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
@en
P2093
P2860
P356
P1476
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
@en
P2093
Astrid Maass
Joachim C Burbiel
P2860
P304
P356
10.1517/14728214.8.2.537
P407
P577
2003-11-01T00:00:00Z